A Delaware district judge was right to dismiss Amgen’s attempt to allege infringement of a US purification patent by Coherus’ Udenyca pegfilgrastim biosimilar, the US Court of Appeals for the Federal Circuit has ruled. Coherus launched Udenyca at the start of this year, and anticipates the biosimilar generating sales of $79m to $84m in the second quarter of 2019.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?